Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples.

Halperin RF, Liang WS, Kulkarni S, Tassone EE, Adkins J, Enriquez D, Tran NL, Hank NC, Newell J, Kodira C, Korn R, Berens ME, Kim S, Byron SA.

Front Oncol. 2019 Mar 20;9:119. doi: 10.3389/fonc.2019.00119. eCollection 2019.

2.

A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.

Mueller S, Jain P, Liang WS, Kilburn L, Kline C, Gupta N, Panditharatna E, Magge SN, Zhang B, Zhu Y, Crawford JR, Banerjee A, Nazemi K, Packer RJ, Petritsch CK, Truffaux N, Roos A, Nasser S, Phillips JJ, Solomon D, Molinaro A, Waanders AJ, Byron SA, Berens ME, Kuhn J, Nazarian J, Prados M, Resnick AC.

Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32258. [Epub ahead of print]

PMID:
30861105
3.

Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data.

Yang W, Warrington NM, Taylor SJ, Whitmire P, Carrasco E, Singleton KW, Wu N, Lathia JD, Berens ME, Kim AH, Barnholtz-Sloan JS, Swanson KR, Luo J, Rubin JB.

Sci Transl Med. 2019 Jan 2;11(473). pii: eaao5253. doi: 10.1126/scitranslmed.aao5253.

PMID:
30602536
4.

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.

Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, Gupta N, Myseros JS, Hwang EI, Kline C, Crawford JR, Warren KE, Cha S, Liang WS, Berens ME, Packer RJ, Resnick AC, Prados M, Mueller S, Nazarian J.

Clin Cancer Res. 2018 Dec 1;24(23):5850-5859. doi: 10.1158/1078-0432.CCR-18-1345. Epub 2018 Oct 15.

5.

Sex-specific gene and pathway modeling of inherited glioma risk.

Ostrom QT, Coleman W, Huang W, Rubin JB, Lathia JD, Berens ME, Speyer G, Liao P, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Houlston RS, Il'yasova D, Jenkins RB, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M; GliomaScan consortium , Melin B, Bondy ML, Barnholtz-Sloan JS.

Neuro Oncol. 2019 Jan 1;21(1):71-82. doi: 10.1093/neuonc/noy135.

PMID:
30124908
6.

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM.

Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24.

PMID:
29798906
7.

An anatomic transcriptional atlas of human glioblastoma.

Puchalski RB, Shah N, Miller J, Dalley R, Nomura SR, Yoon JG, Smith KA, Lankerovich M, Bertagnolli D, Bickley K, Boe AF, Brouner K, Butler S, Caldejon S, Chapin M, Datta S, Dee N, Desta T, Dolbeare T, Dotson N, Ebbert A, Feng D, Feng X, Fisher M, Gee G, Goldy J, Gourley L, Gregor BW, Gu G, Hejazinia N, Hohmann J, Hothi P, Howard R, Joines K, Kriedberg A, Kuan L, Lau C, Lee F, Lee H, Lemon T, Long F, Mastan N, Mott E, Murthy C, Ngo K, Olson E, Reding M, Riley Z, Rosen D, Sandman D, Shapovalova N, Slaughterbeck CR, Sodt A, Stockdale G, Szafer A, Wakeman W, Wohnoutka PE, White SJ, Marsh D, Rostomily RC, Ng L, Dang C, Jones A, Keogh B, Gittleman HR, Barnholtz-Sloan JS, Cimino PJ, Uppin MS, Keene CD, Farrokhi FR, Lathia JD, Berens ME, Iavarone A, Bernard A, Lein E, Phillips JW, Rostad SW, Cobbs C, Hawrylycz MJ, Foltz GD.

Science. 2018 May 11;360(6389):660-663. doi: 10.1126/science.aaf2666.

8.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

9.

Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.

Ostrom QT, Kinnersley B, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Rubin JB, Lathia JD, Berens ME, Andersson U, Rajaraman P, Chanock SJ, Linet MS, Wang Z, Yeager M; GliomaScan consortium, Houlston RS, Jenkins RB, Melin B, Bondy ML, Barnholtz-Sloan JS.

Sci Rep. 2018 May 9;8(1):7352. doi: 10.1038/s41598-018-24580-z.

10.

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.

Bollam SR, Berens ME, Dhruv HD.

Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):15. doi: 10.1007/s11910-018-0825-7. Review.

PMID:
29525892
11.

Females have the survival advantage in glioblastoma.

Ostrom QT, Rubin JB, Lathia JD, Berens ME, Barnholtz-Sloan JS.

Neuro Oncol. 2018 Mar 27;20(4):576-577. doi: 10.1093/neuonc/noy002. No abstract available.

12.

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition.

Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT.

Nature. 2017 Nov 9;551(7679):247-250. doi: 10.1038/nature24297. Epub 2017 Nov 1.

13.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

14.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

15.

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL.

Nature. 2017 Jul 27;547(7664):453-457. doi: 10.1038/nature23007. Epub 2017 Jul 5.

16.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2017 Jun 13;19(11):2410-2412. doi: 10.1016/j.celrep.2017.05.039. No abstract available.

17.

Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.

Vitucci M, Irvin DM, McNeill RS, Schmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AM, Bash RE, Kim S, Berens ME, Miller CR.

Neuro Oncol. 2017 Sep 1;19(9):1237-1247. doi: 10.1093/neuonc/nox050.

18.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

19.

Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL.

Oncotarget. 2017 Feb 14;8(7):12234-12246. doi: 10.18632/oncotarget.14685.

20.

Integrated genomic analysis of survival outliers in glioblastoma.

Peng S, Dhruv H, Armstrong B, Salhia B, Legendre C, Kiefer J, Parks J, Virk S, Sloan AE, Ostrom QT, Barnholtz-Sloan JS, Tran NL, Berens ME.

Neuro Oncol. 2017 Jun 1;19(6):833-844. doi: 10.1093/neuonc/now269. Erratum in: Neuro Oncol. 2017 Apr 1;19(4):601.

21.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2016 Jul 26;16(4):950-966. doi: 10.1016/j.celrep.2016.06.045. Epub 2016 Jul 7. Erratum in: Cell Rep. 2017 Jun 13;19(11):2410-2412.

22.

Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma.

Markowitz D, Powell C, Tran NL, Berens ME, Ryken TC, Vanan M, Rosen L, He M, Sun S, Symons M, Al-Abed Y, Ruggieri R.

Mol Cancer Ther. 2016 Aug;15(8):1799-808. doi: 10.1158/1535-7163.MCT-15-0849. Epub 2016 May 20.

23.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

24.

Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.

Dhruv HD, Roos A, Tomboc PJ, Tuncali S, Chavez A, Mathews I, Berens ME, Loftus JC, Tran NL.

J Neurooncol. 2016 Feb;126(3):397-404. doi: 10.1007/s11060-015-1981-0. Epub 2015 Nov 12.

25.

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.

Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.

J Transl Med. 2015 Sep 17;13:306. doi: 10.1186/s12967-015-0667-x.

26.

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma.

Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, Sontheimer H.

Sci Transl Med. 2015 May 27;7(289):289ra86. doi: 10.1126/scitranslmed.aaa8103.

27.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

28.

Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma.

Householder KT, DiPerna DM, Chung EP, Wohlleb GM, Dhruv HD, Berens ME, Sirianni RW.

Int J Pharm. 2015 Feb 20;479(2):374-80. doi: 10.1016/j.ijpharm.2015.01.002. Epub 2015 Jan 3.

29.

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S.

Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196.

30.

Targeting adaptive glioblastoma: an overview of proliferation and invasion.

Xie Q, Mittal S, Berens ME.

Neuro Oncol. 2014 Dec;16(12):1575-84. doi: 10.1093/neuonc/nou147. Epub 2014 Jul 30. Review.

31.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis.

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, DiPerna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL.

PLoS One. 2014 Jan 29;9(1):e85448. doi: 10.1371/journal.pone.0085448. eCollection 2014.

32.

Detection of an atypical teratoid rhabdoid brain tumor gene deletion in circulating blood using next-generation sequencing.

Chakravadhanula M, Tembe W, Legendre C, Carpentieri D, Liang WS, Bussey KJ, Carpten J, Berens ME, Bhardwaj RD.

J Child Neurol. 2014 Sep;29(9):NP81-5. doi: 10.1177/0883073813503904. Epub 2013 Oct 17.

PMID:
24141276
33.

Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival.

Teng L, Nakada M, Furuyama N, Sabit H, Furuta T, Hayashi Y, Takino T, Dong Y, Sato H, Sai Y, Miyamoto K, Berens ME, Zhao SG, Hamada J.

Neuro Oncol. 2013 Dec;15(12):1710-20. doi: 10.1093/neuonc/not128. Epub 2013 Oct 11.

34.

Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression.

Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL.

Front Oncol. 2013 Oct 4;3:241. doi: 10.3389/fonc.2013.00241. Review.

35.

Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.

Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, Berens ME, Tran NL, Meurice N.

J Biol Chem. 2013 Nov 8;288(45):32261-76. doi: 10.1074/jbc.M113.493536. Epub 2013 Sep 20.

36.

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Dhruv HD, Whitsett TG, Jameson NM, Patel F, Winkles JA, Berens ME, Tran NL.

Carcinogenesis. 2014 Jan;35(1):218-26. doi: 10.1093/carcin/bgt289. Epub 2013 Aug 23.

37.

Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.

Dhruv HD, McDonough Winslow WS, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Loftus JC, Tran NL, Berens ME.

PLoS One. 2013 Aug 15;8(8):e72134. doi: 10.1371/journal.pone.0072134. eCollection 2013.

38.

Clinical trials in cellular immunotherapy for brain/CNS tumors.

Badhiwala J, Decker WK, Berens ME, Bhardwaj RD.

Expert Rev Neurother. 2013 Apr;13(4):405-24. doi: 10.1586/ern.13.23. Review.

PMID:
23545055
39.

RTK inhibition: looking for the right pathways toward a miracle.

Xie Q, Vande Woude GF, Berens ME.

Future Oncol. 2012 Nov;8(11):1397-400. doi: 10.2217/fon.12.130.

PMID:
23148613
40.

The small GTPase RhoG mediates glioblastoma cell invasion.

Kwiatkowska A, Didier S, Fortin S, Chuang Y, White T, Berens ME, Rushing E, Eschbacher J, Tran NL, Chan A, Symons M.

Mol Cancer. 2012 Sep 11;11:65. doi: 10.1186/1476-4598-11-65.

41.

Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling.

Creamer MS, Stites EC, Aziz M, Cahill JA, Tan CW, Berens ME, Han H, Bussey KJ, Von Hoff DD, Hlavacek WS, Posner RG.

BMC Syst Biol. 2012 Aug 22;6:107. doi: 10.1186/1752-0509-6-107.

42.

miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2.

Loftus JC, Ross JT, Paquette KM, Paulino VM, Nasser S, Yang Z, Kloss J, Kim S, Berens ME, Tran NL.

PLoS One. 2012;7(6):e39818. doi: 10.1371/journal.pone.0039818. Epub 2012 Jun 22.

43.

Stable gene selection from microarray data via sample weighting.

Yu L, Han Y, Berens ME.

IEEE/ACM Trans Comput Biol Bioinform. 2012 Jan-Feb;9(1):262-72. doi: 10.1109/TCBB.2011.47. Epub 2011 Mar 3.

PMID:
21383420
44.

The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.

Nakada M, Anderson EM, Demuth T, Nakada S, Reavie LB, Drake KL, Hoelzinger DB, Berens ME.

Int J Cancer. 2010 Mar 1;126(5):1155-65. doi: 10.1002/ijc.24849.

45.

The Pyk2 FERM domain as a target to inhibit glioma migration.

Loftus JC, Yang Z, Tran NL, Kloss J, Viso C, Berens ME, Lipinski CA.

Mol Cancer Ther. 2009 Jun;8(6):1505-14. doi: 10.1158/1535-7163.MCT-08-1055. Epub 2009 Jun 9.

46.

NHERF-1: modulator of glioblastoma cell migration and invasion.

Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME.

Neoplasia. 2009 Apr;11(4):377-87.

47.

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.

Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL.

Int J Cancer. 2009 Jun 1;124(11):2719-27. doi: 10.1002/ijc.24240.

48.

The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma.

Salhia B, Tran NL, Chan A, Wolf A, Nakada M, Rutka F, Ennis M, McDonough WS, Berens ME, Symons M, Rutka JT.

Am J Pathol. 2008 Dec;173(6):1828-38. doi: 10.2353/ajpath.2008.080043. Epub 2008 Nov 13.

49.
50.

Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3.

Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, Nita M, Berens ME, Sander LM, Newton HB, Chiocca EA, Lawler S.

Neuro Oncol. 2008 Oct;10(5):690-9. doi: 10.1215/15228517-2008-041. Epub 2008 Aug 20.

Supplemental Content

Loading ...
Support Center